Conference Coverage
Latest News
Aug 13, 2026 | News
Published LITESPARK-011 data show PFS benefit with belzutifan plus lenvatinib in ccRCC
Nima Almassi, MD, highlights long-term data on bladder preservation in MIBC
Aug 13, 2026
How urodynamics reshaped the goals of urologic reconstruction
Aug 13, 2026
Higher intake of ultra-processed food associated with increased prostate cancer risk
Aug 12, 2026
Pearls & Perspectives: Patient Expectations, Physician Autonomy, and Life Beyond Surgery, With Andrew T. Cohen, MD, FACS
Aug 12, 2026
Advertisement
Shorts
0:46
Testosterone therapy in women: Rethinking pre- and postmenopausal categories
a day ago
by
Jessica M. Yih, MD
0:21
IVF and voiding symptoms: Start with cycle timing
2 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
1:01
The UroOnc Minute: The importance of BCG maintenance in NMIBC
3 days ago
by
Adam B. Weiner, MD(+1 more)
1:04
Keith Xavier, MD, URPS, shares early experience with Altaviva for male urge incontinence
6 days ago
by
Keith Xavier, MD, URPS
1:09
Adam B. Murphy, MD, MBA, MSCI, urges thoughtful AI integration to prevent clinician burnout
7 days ago
by
Adam B. Murphy, MD, MBA, MSCI
0:36
Joshua Lang, MD, MS, on matching treatment intensity to tumor biology
8 days ago
by
Joshua Lang, MD, MS
0:36
Joshua Halpern, MD, on the advantages of mail-in semen analysis
9 days ago
by
Joshua Halpern, MD, MS
0:59
EV/pembro approval: Translating the science into global care
10 days ago
by
María Natalia Gandur Quiroga, MD, MSc
1:08
Janelle Bunce, PA-C, discusses a holistic approach to testosterone deficiency care
13 days ago
by
Janelle Bunce, PA-C
0:45
Matthew Galsky, MD, on the changing role of cisplatin eligibility in MIBC
14 days ago
by
Matthew Galsky, MD
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
Narmina Khanmammadova, MD, discusses interim findings on preoperative pelvic floor therapy and its potential to improve continence recovery after HoLEP.
Jessica Yih, MD, reviews evidence on testosterone therapy for female sexual dysfunction, highlighting promising but limited data in premenopausal women.
A claims-based analysis found blue light cystoscopy was associated with increase health care resource utilization in NMIBC without significantly increasing total costs.
A real-world analysis found that achieving a PSA level below 0.2 ng/mL was associated with improved overall survival in mCSPC.
These FAQs highlight key recommendations and practical takeaways from the 2026 AUA/ASTRO Clinically Localized Prostate Cancer guideline amendment.
The phase 3 PSMAddition trial found that adding lutetium Lu 177 vipivotide tetraxetan to ADT and an ARPI significantly improved rPFS in mHSPC.
Elizabeth Nally, MBBS, highlights the impact of long-term immunotherapy toxicity and the need for patient-informed approaches to treatment decisions.
In this episode of The UroOnc Minute, Mark D. Tyson, II, MD, MPH, discusses the importance of BCG maintenance therapy in NMIBC and shares strategies for navigating treatment barriers and toxicity.
Keith Xavier, MD, discusses the role of Altaviva in treating men with overactive bladder and urge urinary incontinence, including patient selection, clinical considerations, and its place among third-line therapies.
Abraham Morgentaler, MD, joins Neil Baum, MD, to discuss the historical origins of the belief that testosterone drives prostate cancer and the new framework presented in his recent Journal of Urology publication.
Advertisement
The registrational trial will compare ivonescimab plus enfortumab vedotin vs pembrolizumab plus enfortumab vedotin for locally advanced or metastatic urothelial carcinoma.
Amy Pearlman, MD, and guests Larry Lipshultz, MD, and Elliot Justin, MD, explore the potential of wearable technology to advance the diagnosis, monitoring, and optimization of sexual health for both men and women.
The next-generation implant is designed to extend the implant longevity from 10 years to 15 years.
A recap of the FDA submissions and regulatory decisions in urology from July 2026.
Alan Bryce, MD, breaks down the key prostate cancer studies that he believes are going to change practice from ASCO 2026.
Advertisement
Advertisement
Trending on Urology Times
1
Higher intake of ultra-processed food associated with increased prostate cancer risk
2
Jessica Yih, MD, highlights data on testosterone therapy in women
3
Real-world data support PSA below 0.2 ng/mL as key response threshold in mCSPC
4
Nima Almassi, MD, highlights long-term data on bladder preservation in MIBC
5